# Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

> **NCT03713294** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 37 (actual)

## Conditions studied

- Refractory Plasma Cell Myeloma

## Interventions

- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Elotuzumab
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT03713294
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-14
- **Primary completion:** 2024-02-20
- **Final completion:** 2024-11-14
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03713294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03713294, "Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03713294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*